Type 17 T-helper cells might be a promising therapeutic target for osteoporosis

Molecular Biology Reports

Volumn 39, Issue 1, 2012, Pages 771-774

  Yuan, Feng Lai ^a   Li, Xia ^a   Lu, Wei Guo ^a   Zhao, Yi Qing ^a   Li, Cheng Wan ^a   Li, Jian Ping ^a   Sun, Jun Ming ^a   Xu, Rui Sheng ^a  

^a NANTONG UNIVERSITY   (China)

Author keywords

Cytokines; Osteoclasts; Osteoporosis; Type 17 T helper cells

Indexed keywords

CYTOKINE; INTERLEUKIN 1 RECEPTOR TYPE II; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 23; INTERLEUKIN 23P19; OSTEOCLAST DIFFERENTIATION FACTOR;

ARTHRITIS; ARTICLE; CELL FUNCTION; CELL STIMULATION; CELLULAR IMMUNITY; CYTOKINE RELEASE; CYTOKINE RESPONSE; HUMAN; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE MIGRATION; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; TARGET CELL; TH1 CELL; TH17 CELL; TH2 CELL;

BONE RESORPTION; CELL DIFFERENTIATION; HUMANS; INTERLEUKIN-17; MODELS, BIOLOGICAL; OSTEOCLASTS; OSTEOPOROSIS; TH1 CELLS; TH17 CELLS; TH2 CELLS;

ANIMALIA;

EID: 84855192948     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-011-0797-z     Document Type: Article

References (22)

1. E Canalis 2010 Update in new anabolic therapies for osteoporosis J Clin Endocrinol Metab 95 1496 1504 20375217 10.1210/jc.2009-2677 1:CAS:528: DC%2BC3cXltFSgtbc%3D
2. H Takayanagi 2010 New immune connections in osteoclast formation Ann NY Acad Sci 1192 117 123 20392226 10.1111/j.1749-6632.2009.05303.x 1:CAS:528:DC%2BC3cXmsVSrsL0%3D
3. FL Yuan X Li WG Lu, et al. 2010 Regulatory T cells as a potent target for controlling bone loss Biochem Biophys Res Commun 402 173 176 20920469 10.1016/j.bbrc.2010.09.120 1:CAS:528:DC%2BC3cXhsValsbbE
4. FL Yuan W Hu WG Lu, et al. 2011 Targeting interleukin-21 in rheumatoid arthritis Mol Biol Rep 38 1717 1721 20848219 10.1007/s11033-010-0285-x 1:CAS:528:DC%2BC3MXhtlenu70%3D
5. H Takayanagi 2009 Osteoimmunology and the effects of the immune system on bone Nat Rev Rheumatol 5 667 676 19884898 10.1038/nrrheum.2009.217 1:CAS:528:DC%2BD1MXhsVyntL%2FE
6. HF Pan DQ Ye XP Li 2008 Type 17 T-helper cells might be a promising therapeutic target for systemic lupus erythematosus Nat Clin Pract Rheumatol 4 352 353 18477998 1:CAS:528:DC%2BD1cXnvVKgtbc%3D (Pubitemid 351974005)
7. L Rifas MN Weitzmann 2009 A novel T cell cytokine, secreted osteoclastogenic factor of activated T cells, induces osteoclast formation in a RANKL-independent manner Arthritis Rheum 60 3324 3335 19877052 10.1002/art.24877 1:CAS:528:DC%2BD1MXhsFentLzM
8. FL Yuan X Li WG Lu, et al. 2010 The vacuolar ATPase in bone cells: a potential therapeutic target in osteoporosis Mol Biol Rep 37 3561 3566 20182803 10.1007/s11033-010-0004-7 1:CAS:528:DC%2BC3cXhtFKrsbrF
9. RR McLean 2009 Proinflammatory cytokines and osteoporosis Curr Osteoporos Rep 7 134 139 19968917 10.1007/s11914-009-0023-2
10. IB McInnes G Schett 2007 Cytokines in the pathogenesis of rheumatoid arthritis Nat Rev Immunol 7 429 442 17525752 10.1038/nri2094 1:CAS:528:DC%2BD2sXls1Kgt74%3D (Pubitemid 46834849)
11. K Redlich S Hayer R Ricci, et al. 2002 Osteoclasts are essential for TNF-alpha-mediated joint destruction J Clin Invest 110 1419 1427 12438440 1:CAS:528:DC%2BD38XovFOnu7s%3D (Pubitemid 35396913)
12. K Sato A Suematsu K Okamoto, et al. 2006 Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction J Exp Med 203 2673 2682 17088434 10.1084/jem.20061775 1:CAS:528:DC%2BD28Xht12htLfJ (Pubitemid 44833343)
13. JM Kramer SL Gaffen 2007 Interleukin-17: a new paradigm in inflammation, autoimmunity, and therapy J Periodontol 78 1083 1093 17539723 10.1902/jop.2007.060392
14. JM Quinn NA Sims H Saleh, et al. 2008 IL-23 inhibits osteoclastogenesis indirectly through lymphocytes and is required for the maintenance of bone mass in mice J Immunol 181 5720 5729 18832731 1:CAS:528:DC%2BD1cXhtF2hsLzK
15. F Annunziato L Cosmi F Liotta, et al. 2009 Type 17 T-helper cells-origins, features and possible roles in rheumatic disease Nat Rev Rheumatol 5 325 331 19434074 10.1038/nrrheum.2009.80 1:CAS:528: DC%2BD1MXms12gtL4%3D
16. S Kamiya C Nakamura T Fukawa, et al. 2007 Effects of IL-23 and IL-27 on osteoblasts and osteoclasts: inhibitory effects on osteoclast differentiation J Bone Miner Metab 25 277 285 17704992 10.1007/s00774-007-0766-8 1:CAS:528:DC%2BD2sXpt1Crtb8%3D (Pubitemid 47283267)
17. T Yago Y Nanke N Ichikawa, et al. 2009 IL-17 induces osteoclastogenesis from human monocytes alone in the absence of osteoblasts, which is potently inhibited by anti-TNF-alpha antibody: a novel mechanism of osteoclastogenesis by IL-17 J Cell Biochem 108 947 955 19728295 10.1002/jcb.22326 1:CAS:528:DC%2BD1MXhtlSqs7rN
18. X Li FL Yuan WG Lu, et al. 2010 The role of interleukin-17 in mediating joint destruction in rheumatoid arthritis Biochem Biophys Res Commun 397 131 135 20513356 10.1016/j.bbrc.2010.05.111 1:CAS:528:DC%2BC3cXotVChtbY%3D
19. E Lubberts L van den Bersselaar B Oppers-Walgreen, et al. 2003 IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance J Immunol 170 2655 2662 12594294 1:CAS:528:DC%2BD3sXht12htLc%3D (Pubitemid 36245658)
20. KA Bush KM Farmer JS Walker, et al. 2002 Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein Arthritis Rheum 46 802 805 11920418 10.1002/art.10173 1:CAS:528:DC%2BD38XisFOmtLs%3D (Pubitemid 34214263)
21. M Chabaud P Miossec 2001 The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model Arthritis Rheum 44 1293 1303 11407688 10.1002/1529-0131(200106)44:6<1293:: AID-ART221>3.0.CO;2-T 1:CAS:528:DC%2BD38XpsV0%3D (Pubitemid 32537527)
22. T Korn M Oukka V Kuchroo, et al. 2007 Th17 cells: effector T cells with inflammatory properties Semin Immunol 19 362 371 18035554 10.1016/j.smim.2007. 10.007 1:CAS:528:DC%2BD1cXisVSrsLs%3D (Pubitemid 351274046)